以糖蛋白类肿瘤标志物为靶向的嵌合抗原受体修饰T细胞研究进展

摘要

嵌合抗原受体(chimericantigenreceptor,CAR)修饰T细胞是目前肿瘤治疗中新的靶向疗法,通过单链抗体(singlechainfragmentvariable,scFv)-共刺激分子-T细胞信号转导区构成的嵌合模式修饰T细胞,赋予T细胞非MHC依赖性靶向杀伤肿瘤细胞的能力,在动物模型及临床试验中取得了良好的效果.糖蛋白类肿瘤标志物由于其良好的靶向性成为了CAR修饰T细胞新的靶点,针对糖蛋白类肿瘤标志物的靶向研究显示出良好的临床前景,但是也考虑到脱靶效应,转染方式等问题对该治疗在临床运用的限制.相信随着研究的逐渐深入,基于CAR修饰T细胞的糖蛋白类肿瘤标志物靶向治疗会取得更大的突破.%Chimeric antigen receptor (CAR) modiifed T cells is an emerging targeted therapy, CAR is consisted of single chain fragment variable (scFv), costimulatory molecules and T cells signal transduction domain, which could make T cells non-MHC-restricted targeting kill tumor cells. Experiments of CAR modified T cells in both animal models and clinical practice have got satisfied results. Glycoprotein tumor markers are promising targets of CAR modiifed T cells because of their favorable targeting. Targeted therapy researches aim at glycoprotein tumor marker revealed bright prospects in clinical applications. Nevertheless, some questions like off-target effect and disputed transfection ways should be considered as potential restricted factors in clinical application. We believe CAR modified T cells therapy targeted glycoprotein tumor marker could get more breakthroughs with in-depth researches.